A Study of JNJ-78278343 and JNJ-95298177 for Prostate Cancer
Phase 1
140
about 2.2 years
18+
Male only
4 sites in FL, NY, OH +1
About this study
This trial is testing a treatment combination (JNJ-78278343 and JNJ-95298177) to see if it's safe and effective in treating prostate cancer. The goal is to find the best dose of this combination for people with advanced, hormone-resistant prostate cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take JNJ-78278343
- 2.Take JNJ-95298177
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Adverse Events (AEs) by Severity, Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Secondary: Duration of Response (DOR), Objective Response Rate (ORR), Prostate-Specific Antigen (PSA) Response Rate, Radiographic Progression-Free Survival (rPFS), Time to Response (TTR)
Oncology